Empagliflozin - Boehringer Ingelheim/Eli Lilly

Drug Profile

Empagliflozin - Boehringer Ingelheim/Eli Lilly

Alternative Names: BI-10773; Jardiance

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly; Medical University of Vienna; Yale University
  • Class Antihyperglycaemics; Benzhydryl compounds; Cyclic ethers; Glucosides; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Type 2 diabetes mellitus
  • Phase III Type 1 diabetes mellitus
  • Phase II Heart failure; Renal failure

Most Recent Events

  • 11 Nov 2017 Updated efficacy data from the phase III EMPA-REG OUTCOME trial in Type II diabetes presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA/ASA-2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in Austria (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in Canada (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top